Read more about this disease, some with Classification – Types – Signs and symptoms – Genetics – Pathophysiology – Diagnosis – Screening – Prevention – Treatment and management – Cures and much more, some including pictures and video when available.
Paroxysmal nocturnal hemoglobinuria (PNH), sometimes referred to as Marchiafava-Micheli syndrome, is a rare, acquired, potentially life-threatening disease of the blood characterised by complement-induced hemolytic anemia (anemia due to destruction of red blood cells in the bloodstream), red urine (due to the appearance of hemoglobin in the urine) and thrombosis. PNH is the only hemolytic anemia caused by an acquired (rather than inherited) intrinsic defect in the cell membrane (deficiency of glycophosphatidylinositol leading to absence of protective proteins on the membrane)[1]. It may develop on its own (“primary PNH”) or in the context of other bone marrow disorders such as aplastic anemia (“secondary PNH”).
Treatment is usually supportive (blood transfusion for anemia, anticoagulation for thrombosis), although the monoclonal antibody eculizumab (Soliris) is being used to treat some cases.[2]
Most people with “primary PNH” have red urine at some point in their disease course. Many of them continue to have low-grade breakdown of red blood cells, leading to anemia. Typical symptoms of anemia are tiredness, shortness of breath and palpitations. On laboratory examination of the urine, breakdown products of red blood cells (hemoglobin and hemosiderin) may be identified.[2] A small proportion of patients report abdominal pain, dysphagia (difficulty swallowing) and odynophagia (pain during swallowing), as well as erectile dysfunction in men – this occurs mainly when the breakdown of red blood cells is rapid.[2]
Forty percent of patients develop thrombosis (a blood clot) at some point in their illness. This is the main cause of severe complications and death in PNH. These may develop in common sites (deep vein thrombosis of the leg veins and resultant pulmonary embolism when these clots break off and enter the lungs), but in PNH blood clots may also form in more unusual sites: the hepatic vein (causing Budd-Chiari syndrome), the portal vein of the liver (causing portal vein thrombosis), the superior or inferior mesenteric vein (causing mesenteric ischemia) and veins of the skin. Cerebral venous thrombosis, an uncommon form of stroke, is more common in PNH.[2]
Blood tests in PNH show changes consistent with hemolytic anemia: low hemoglobin, raised lactate dehydrogenase, raised reticulocytes (immature red cells released by the bone marrow to replace the destroyed cells), raised bilirubin (a breakdown product of hemoglobin) and decreased levels of haptoglobin. The direct antiglobulin test (DAT, or direct Coombs’ test) is negative, as the hemolysis of PNH is not caused by antibodies.[2]
A sugar or sucrose lysis test, in which a patient’s red blood cells are placed in low ionic strength solution and observed for hemolysis, is used for screening. A more specific test for PNH, called Ham’s acid hemolysis (after Dr Thomas Ham, who described the test in 1937) test, is performed if the sugar test is positive for hemolysis.[3] More sensitive modern methods include flow cytometry for CD55 and CD59 on white and red blood cells. Dependent on the presence of these molecules on the cell surface, they are classified as type I, II or III PNH cells. Type I cells have normal levels of CD55 and CD59, type II have reduced levels and type III have absent levels. The higher the number of type III cells, the higher the risk of hemolysis and thrombosis.[2]
PNH is classified by the context under which it is diagnosed:[2]
[tubepress mode=’tag’, tagValue=’Paroxysmal nocturnal hemoglobinuria’]